Book contents
- Infectious Diseases, Microbiology and Virology
- Infectious Diseases, Microbiology and Virology
- Copyright page
- Contents
- Preface
- Reference Ranges
- Abbreviations
- Chapter 1 Biology of Bacteria, Viruses, Fungi and Parasites and the Host–Pathogen Interactions
- Chapter 2 Microbiology and Virology Laboratory Practice
- Chapter 3 Health and Safety for Infectious Diseases, Microbiology and Virology
- Chapter 4 Principles of Public Health in Relation to Infectious Diseases, Microbiology and Virology
- Chapter 5 Infection Prevention and Control
- Chapter 6 Important Clinical Syndromes Presenting from the Community and within Healthcare Organisations
- Chapter 7 Understanding the Use of Antimicrobial Agents
- Chapter 8 Vaccination
- Chapter 9 The Management of HIV Infection, Opportunistic Infections and Complications of Other Causes of Immunocompromise
- Chapter 10 Travel and Geographical Health; Imported Infection and the Provision of Pre-travel Health Advice
- Index
- References
Chapter 7 - Understanding the Use of Antimicrobial Agents
Published online by Cambridge University Press: 19 December 2019
Book contents
- Infectious Diseases, Microbiology and Virology
- Infectious Diseases, Microbiology and Virology
- Copyright page
- Contents
- Preface
- Reference Ranges
- Abbreviations
- Chapter 1 Biology of Bacteria, Viruses, Fungi and Parasites and the Host–Pathogen Interactions
- Chapter 2 Microbiology and Virology Laboratory Practice
- Chapter 3 Health and Safety for Infectious Diseases, Microbiology and Virology
- Chapter 4 Principles of Public Health in Relation to Infectious Diseases, Microbiology and Virology
- Chapter 5 Infection Prevention and Control
- Chapter 6 Important Clinical Syndromes Presenting from the Community and within Healthcare Organisations
- Chapter 7 Understanding the Use of Antimicrobial Agents
- Chapter 8 Vaccination
- Chapter 9 The Management of HIV Infection, Opportunistic Infections and Complications of Other Causes of Immunocompromise
- Chapter 10 Travel and Geographical Health; Imported Infection and the Provision of Pre-travel Health Advice
- Index
- References
Summary
A basic understanding of the mechanism of action and indication for antimicrobials is held by most prescribers. The key properties of different classes of antimicrobials, their anticipated side effects and the spectrum of activity against different pathogens is inherent in most undergraduate and post-graduate medical curricula. Practitioners in the fields of infectious diseases, microbiology and virology must have a firm grasp of this knowledge, and should be able to apply it to patients with bacterial, viral, fungal or parasitic infections. They must be able to integrate this knowledge with the pharmacokinetic properties of the antimicrobials, and should be able to adapt this in differing patient populations including those with renal impairment or on renal replacement therapy and those with allergies or other host factors.
- Type
- Chapter
- Information
- Infectious Diseases, Microbiology and VirologyA Q&A Approach for Specialist Medical Trainees, pp. 154 - 178Publisher: Cambridge University PressPrint publication year: 2019
References
Further Reading
Department of Health, UK Government. Measles: post-exposure prophylaxis. 2009;5. Available at: www.gov.uk/government/publications/measles-post-exposure-prophylaxisGoogle Scholar
Further Reading
Davies, BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010;65(S2):5–10.Google Scholar
Further Reading
NICE Technology Appraisal Guidance [TA168]. Amantadine, oseltamivir and zanamivir for the treatment of influenza. 2009. Available at: www.nice.org.uk/guidance/ta168Google Scholar
Further Reading
Wang, JL, Tang, HJ, Hsieh, PH, Chiu, FY, Chen, YH, Chang, MC, Huang, CT, Liu, CP, Lau, YJ, Hwang, KP, Ko, WC, Wang, CT, Liu, CY, Liu, CL, Hsueh, PR. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2012;40(2):103–107.Google Scholar
Further Reading
Jackson, J, Chen, C, Buising, K. Aminoglycosides: how should we use them in the 21st century? Curr Opin Infect Dis. 2013;26(6):516–525.Google Scholar
Further Reading
Jackson, J, Chen, C, Buising, K. Aminoglycosides: how should we use them in the 21st century? Curr Opin Infect Dis. 2013;26(6):516–525.Google Scholar
Further Reading
Bookstaver, PB, Bland, CM, Griffin, B, Stover, KR, Eiland, LS, McLaughlin, M. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052–1062.CrossRefGoogle ScholarPubMed
Further Reading
Donald, PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 2010;90(5):279–292.Google Scholar
Further Reading
Horsburg, R, Barry, CE, Lange, C. Treatment of tuberculosis. N Engl J Med. 2015;373:2149–2160.Google Scholar
Further Reading
Reinert, RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15(S3):7–11.Google Scholar
Further Reading
Aldred, KJ, Kerns, RJ, Osheroff, N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):1565–1574.Google Scholar
Further Reading
Forrest, GN, Tamura, K. Rifampicin combination therapy for non-mycobacterial infections. Clin Microbiol Rev. 2010;23(1):14–34.Google Scholar
Further Reading
Forrest, GN, Tamura, K. Rifampicin combination therapy for non-mycobacterial infections. Clin Microbiol Rev. 2010;23(1):14–34.Google Scholar
Further Reading
Shane, AL, Mody, RK, Crump, JA, Tarr, PI, Steiner, TS, Kotloff, K, Langley, JM, Wanke, C, Warren, CA, Cheng, AC, Cantey, J, Pickering, LK. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhoea. Clin Infect Dis. 2017;65(12):1963–1973.Google Scholar
Further Reading
Rodrigues, LC, Lockwood, DN. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis. 2011;11(6):464–470.Google Scholar
Further Reading
Zhang, FR, Liu, H, Irwanto, A, Fu, XA, Li, Y, Yu, GQ, Yu, YX, Chen, MF, Low, HQ, Li, JH, Bao, FF, Foo, JN, Bei, JX, Jia, XM, Liu, J, Liany, H, Wang, N, Niu, GY, Wang, ZZ, Shi, BQ, Tian, HQ, Liu, HX, Ma, SS, Zhou, Y, You, JB, Yang, Q, Wang, C, Chu, TS, Liu, DC, Yu, XL, Sun, YH, Ning, Y, Wei, ZH, Chen, SL, Chen, XC, Zhang, ZX, Liu, YX, Pulit, SL, Wu, WB, Zheng, ZY, Yang, RD, Long, H, Liu, ZS, Wang, JQ, Li, M, Zhang, LH, Wang, H, Wang, LM, Xiao, P, Li, JL, Huang, ZM, Huang, JX, Li, Z, Liu, J, Xiong, L, Yang, J, Wang, XD, Yu, DB, Lu, XM, Zhou, GZ, Yan, LB, Shen, JP, Zhang, GC, Zeng, YX, de Bakker, PI, Chen, SM, Liu, JJ. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369:1620–1628.Google Scholar
Further Reading
Douros, A, Grabowski, K, Stahlmann, R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol. 2015;11(12):1849–1859.Google Scholar
Dryden, MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(S4):7–15.Google Scholar
Further Reading
Ramsey, TD, Lau, TT, Ensom, MH. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother. 2013;47(4):543–560.CrossRefGoogle ScholarPubMed
Further Reading
Dinos, GP, Athanassopoulos, CM, Missiri, DA, Giannopoulou, PC, Vlachogiannis, IA, Papadopoulos, GE, Papaioannou, D, Kalpaxis, DL. Chloramphenicol derivatives as antibacterial and anticancer agents: historic problems and current solutions. Antibiotics. 2016;5(2):20.Google Scholar
Further Reading
Russell, NJ, Seale, AC, O’Sullivan, C, Le Doare, K, Heath, PT, Lawn, JE, Bartlett, L, Cutland, C, Gravett, M, Ip, M, Madhi, SA, Rubens, CE, Saha, SK, Schrag, S, Sobanjo-Ter Meulen, A, Vekemans, J, Baker, CJ. Risk of early-onset neonatal group B streptococcal disease with maternal colonization worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65(S2):S152–S159.CrossRefGoogle Scholar
Further Reading
Simonsen, KA, Anderson-Berry, AL, Delair, SF, Davies, HD. Early-onset neonatal sepsis. Clin Microbiol Rev. 2014;27(1):21–47.Google Scholar
Further Reading
Gudiol, C, Cuervo, G, Shaw, E, Pujol, M, Carratalà, J. Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia. Expert Opin Pharmacother. 2017;18(18):1947–1963.Google Scholar
McDanel, JS, Perencevich, EN, Diekema, DJ, Herwaldt, LA, Smith, TC, Chrischilles, EA, Dawson, JD, Jiang, L, Goto, M, Schweizer, ML. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015;61(3):361–367.CrossRefGoogle ScholarPubMed
Thwaites, GE, Scarborough, M, Szubert, A, Nsutebu, E, Tilley, R, Greig, J, Wyllie, SA, Wilson, P, Auckland, C, Cairns, J, Ward, D, Lal, P, Guleri, A, Jenkins, N, Sutton, J, Wiselka, M, Armando, GR, Graham, C, Chadwick, PR, Barlow, G, Gordon, NC, Young, B, Meisner, S, McWhinney, P, Price, DA, Harvey, D, Nayar, D, Jeyaratnam, D, Planche, T, Minton, J, Hudson, F, Hopkins, S, Williams, J, Török, ME, Llewelyn, MJ, Edgeworth, JD, Walker, AS. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10121):668–678.Google Scholar
Further Reading
Habib, G, Lancellotti, P, Antunes, MJ, Bongiorni, MG, Casalta, JP, Del Zotti, F, Dulgheru, R, El Khoury, G, Erba, PA, Lung, B, Miro, JM, Mulder, BJ, Plonska-Gosciniak, E, Price, S, Roos-Hesselink, J, Snygg-Martin, U, Thuny, F, Tornos Mas, P, Vilacosta, I, Zamorano, JL. 2015 ESC guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(44):3075–3128.Google Scholar
Further Reading
Baciewicz, AM, Chrisman, CR, Finch, CK, Self, TH. Update on rifampicin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1–12.Google Scholar
Further Reading
Garneau-Tsodikovaa, S, Labby, KJ. Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. Med Chem Comm. 2016;7(1):11–27.Google Scholar
Hanberger, H, Edlund, C, Furebring, M, G Giske, C, Melhus, A, Nilsson, LE, Petersson, J, Sjölin, J, Ternhag, A, Werner, M, Eliasson, E. Rational use of aminoglycosides – review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand J Infect Dis. 2013;45(3):161–175.Google Scholar
Further Reading
Hayward, RS, Harding, J, Molloy, R, Land, L, Longcroft‐Neal, K, Moore, D, Ross, JDC. Adverse effects of a single dose of gentamicin in adults: a systematic review. Br J Clin Pharmacol. 2018;84(2):223–238.Google Scholar
Huth, ME, Ricci, AJ, Cheng, AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol. 2011;937861.Google Scholar
Further Reading
Gonzalez-Ruiz, A, Seaton, RA, Hamed, K. Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections. Infect Drug Resist. 2016;9:47–58.Google Scholar
Further Reading
Miller, AD, Ball, AM, Brandon Bookstaver, P, Dornblaser, EK, Bennett, CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011;31(4):408–423.Google Scholar
Further Reading
Farrell, DJ, Flamm, RK, Sader, HS, Jones, RN. Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. Antimicrob Agents Chemother. 2014;58(7):3882–3888.Google Scholar
Livermore, DM, Mushtaq, S, Meunier, D, Hopkins, KL, Hill, R, Adkin, R, Chaudhry, A, Pike, R, Staves, P, Woodford, N. Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother. 2017;72(8):2278–2289.Google Scholar
Further Reading
Baciewicz, AM, Chrisman, CR, Finch, CK, Self, TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1–12.CrossRefGoogle ScholarPubMed
Further Reading
Ashbee, HR, Barnes, RA, Johnson, EM, Richardson, MD, Gorton, R, Hope, WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162–1176.Google Scholar
Further Reading
Further Reading
Fleming, S, Yannakou, CK, Haeusler, GM, Clark, J, Grigg, A, Heath, CH, Bajel, A, van Hal, SJ, Chen, SC, Milliken, ST, Morrissey, CO, Tam, CS, Szer, J, Weinkove, R, Slavin, MA. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haematopoietic stem cell transplantation, 2014. Intern Med J. 2014;44(12b):1283–1297.Google Scholar
Robenshtok, E, Gafter-Gvilli, A, Goldberg, E, Weinberger, M, Yeshurun, M, Leibovici, L, Paul, M. Antifungal prophylaxis in cancer patients after chemotherapy or haematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25(34):5471–5489.Google Scholar
Further Reading
Cooley, L, Dendle, C, Wolf, J, The, BW, Chen, SC, Boutlis, C, Thurskey, KA. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014;44(12b):1350–1363.Google Scholar
Further Reading
Czaplewski, L, Bax, R, Martha, C, Clokie, M, Dawson, M, Fairhead, H, Fischetti, VA, Foster, S, Gilmore, BF, Hancock, RE, Harper, D, Henderson, IR, Hilpert, K, Jones, BV, Kadioglu, A, Knowles, D, Ólafsdóttir, S, Payne, D, Projan, S, Shaunak, S, Silverman, J, Thomas, CM, Trust, TJ, Warn, P, Rex, JH. Alternatives to antibiotics – a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–251.Google Scholar